Will US and European guidelines follow the UK's lead and incorporate value metrics in their recommendations? Dr. John Marshall, reporting on a discussion at GICS, says it's only a matter of time.

A new study sheds some light on what clinicians should tell patients about waiting to treat prostate cancer, says Dr Gerald Chodak.

A new study suggests that the ultrasensitive PSA test may help clinicians advise patients post-prostatectomy on whether or not to get adjuvant radiation therapy, says Dr Gerald Chodak.

Dr Paul Offit offers an overview of the recent approval of a new HPV9 vaccine, responds to some of the questions clinicians may have, and describes some research in progress.

Dr David Kerr responds to Richard Smith's provocative blog post, 'Dying of Cancer Is the Best Death,' and calls his fellow Brit 'daft' for saying we should stop spending billions to overcome cancer.

Concomitant high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP) should not preclude the patient from active surveillance, reports Dr Gerald Chodak.

Men with a family history of prostate cancer may be more likely to have prostate cancer themselves, but do they benefit from the screening process? Dr Gerald Chodak discusses the latest research.

Dr Gerald Chodak goes beyond the headlines to examine the new Canadian guidelines for PSA screening.

Too much data entry; continuing worries about malpractice, and the push to squeeze costs are among the challenges that physicians continue to wrestle with.

Dr Gerald Chodak reviews a new study that compared the results of prostate biopsies guided by MRI with those using standard ultrasonography.